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ABSTRACT
NpmA, a methyltransferase that confers resistance
to aminoglycosides was identified in an Escherichia
coli clinical isolate. It belongs to the kanamycin–
apramycin methyltransferase (Kam) family and
specifically methylates the 16S rRNA at the N1
position of A1408. We determined the structures of
apo-NpmA and its complexes with S-adenosyl-
methionine (AdoMet) and S-adenosylhomocysteine
(AdoHcy) at 2.4, 2.7 and 1.68A ˚ , respectively. We
generated a number of NpmA variants with alanine
substitutions and studied their ability to bind the
cofactor, to methylate A1408 in the 30S subunit,
and to confer resistance to kanamycin in vivo.
Residues D30, W107 and W197 were found to be
essential. We have also analyzed the interactions
between NpmA and the 30S subunit by footprinting
experiments and computational docking. Helices 24,
42 and 44 were found to be the main NpmA-binding
site. Both experimental and theoretical analyses
suggest that NpmA flips out the target nucleotide
A1408 to carry out the methylation. NpmA is
plasmid-encoded and can be transferred between
pathogenic bacteria; therefore it poses a threat to
the successful use of aminoglycosides in clinical
practice. The results presented here will assist in
the development of specific NpmA inhibitors that
could restore the potential of aminoglycoside
antibiotics.
INTRODUCTION
Aminoglycosides are bactericidal antibiotics that are
widely used in treatment against severe infectious
diseases caused by Gram-negative and Gram-positive
bacteria. They bind to the 30S subunit of the ribosome
at the A-site and induce a conformational change that is
responsible for the loss of ﬁdelity of the protein translation
process (1). Due to the indiscriminate and excessive use of
these antibiotics, pathogenic bacteria have acquired from
antibiotic producers and further evolved several mechan-
isms of resistance to these antibiotics such as: alteration of
the antibiotic to inactivate it, mutation on the small ribo-
somal subunit, which modiﬁes the target site of the anti-
biotic, or methylation at speciﬁc sites on the 16S rRNA
that prevent the binding of the antibiotic to the ribosome
(2). Mutation of A to G at position 1408 in the 16S rRNA
has been found in clinical isolates of mycobacteria (3).
However, methylation provides high-level resistance
to most aminoglycosides used in the clinical practice. It
is carried out by speciﬁc methyltransferases that are found
in two classes of bacteria: the antibiotic producers and the
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the methyltransferase is usually found on the chromo-
some, whereas in pathogens it is typically present on an
extrachromosomal plasmid (4).
There are two families of methyltransferases that are
responsible for the resistance against aminoglycosides.
These are the Arm (aminoglycoside resistance methyl-
transferase) family (5) and the Kam (kanamycin–
apramycin methyltransferase) family (6), which speciﬁcal-
ly methylate the 16S rRNA at the N7 position of G1405,
and the N1 position of A1408, respectively. Kam enzymes
confer high-level resistance to broad spectrum
aminoglycosides. KamA and KamB have been found in
antibiotic producers, while NpmA from Escherichia coli
clinical strain ARS3 is the ﬁrst methyltransferase found
in a clinical isolate that can methylate 16S rRNA at
m
1A1408 (7). In addition, the npmA gene was found
on a plasmid, so its rapid horizontal transfer among bac-
terial pathogens is expected, which poses a threat to the
successful use of aminoglycoside antibiotics in treatment
of infectious diseases.
Here, we report the crystal structure of NpmA and its
complex with AdoMet and AdoHcy, along with
structure-guided functional and modeling studies.
Residues conserved in the Kam family were substituted
with alanine and the resulting NpmA variants were
analyzed for their methylation activity, for their ability
to bind AdoMet and AdoHcy (by isothermal titration cal-
orimetry), and for their ability to confer resistance to
kanamycin in vivo. In addition, we analyzed the inter-
action of NpmA with the small ribosomal subunit by foot-
printing analyses and computational docking. These
studies provide insight into the mechanism of substrate
recognition and methylation of A1408 by NpmA. The
NpmA structure and the knowledge of its interaction
with the substrate will serve as a starting point for the
development of speciﬁc inhibitors of the Kam family of
methyltransferases that could reinstate aminoglycoside
sensitivity in aminoglycoside-resistant pathogens.
MATERIALS AND METHODS
Cloning and site-directed mutagenesis
The npmA gene synthesis was ordered from the Epoch
Biolabs Inc. following the sequence published in ref. (7).
The npmA gene was subsequently recloned into NdeI and
EcoRI sites of the pET-25b (+) vector with the addition
of a C-terminal non-cleavable (His)6-tag. The amino acid
sequence of NpmA is devoid of methionine. In order to
facilitate the structure determination through SelMet-
labeled protein, we mutated four codons for leucine
residues (L31, L90, L128 and L196) to methionine
codons by inverse PCR (8) using Phusion high-ﬁdelity
DNA polymerase (Finnzymes). Mutations leading to
alanine substitutions of selected conserved amino acids
(D30, D55, E88, P106, W107, W109, F177, S195, W197,
K199, R200 or R205) were introduced either by using
Platinum Pfx DNA polymerase (Invitrogen) in the
PCR-overlapping method (9) or by inverse PCR using
Phusion high-ﬁdelity DNA polymerase (Finnzymes).
All introduced mutations were veriﬁed by DNA
sequencing. Deoxyoligonucleotides used in this work are
listed in Supplementary Table S1.
Expression and puriﬁcation
E. coli BL21 (DE3) was transformed with recombinant
vector pET-25b(+) carrying the npmA gene for protein
expression. E. coli cells were cultured in 1l of LB
medium supplemented with ampicillin (100mg/l) at 37 C
until the OD600 reached 0.5–0.6 AU. The expression was
induced with 150mM IPTG and cells continued to grow at
20 C overnight. Cells were harvested by centrifugation
(9000g, 30min, 4 C), and the pellet was resuspended in
40ml of lysis buffer [50 mM HEPES sodium pH 7.5,
250mM NaCl, 10% glycerol, 0.5% Triton-X 100, 5mM
b-mercaptoethanol (BME) and 1 protease inhibitor tablet
(Roche)].
After sonication the cell lysate was centrifuged at
39191g for 30min at 4 C. The supernatant was allowed
to bind to the Ni-NTA agarose beads (Qiagen) for 1 h at
4 C and was subsequently washed with wash buffer I
(50mM HEPES sodium, pH 7.5, 250mM NaCl, 10%
glycerol, 5mM BME and 5mM imidazole, pH 7.5),
wash buffer II (50mM HEPES sodium, pH 7.5, 1.0 M
NaCl, 10% glycerol, 5mM BME and 10mM imidazole,
pH 7.5) and wash buffer III (50mM HEPES sodium,
pH 7.5, 250mM NaCl, 10% glycerol, 5mM BME and
15mM imidazole, pH 7.5). Finally, the protein was
eluted in three steps using buffer A (50mM HEPES
sodium, pH 7.5, 250mM NaCl, 10% glycerol, 5mM
BME, 200mM imidazole, pH 7.5), buffer B (50mM
HEPES sodium, pH 7.5, 250mM NaCl, 10% glycerol,
5mM BME and 250mM imidazole, pH 7.5) and buffer
C (50mM HEPES sodium, pH 7.5, 250mM NaCl, 10%
glycerol, 5mM BME and 300mM imidazole, pH 7.5). The
eluted protein was loaded onto a size exclusion column
(Superdex 200, GE Healthcare) equilibrated with the
buffer containing 20mM HEPES sodium, pH 7.5,
250mM NaCl, 5% glycerol, 5mM BME and 10mM
MgCl2. The eluted NpmA was concentrated up to
11mg/ml. A similar protocol was adopted to purify the
selenomethionine (SelMet) labeled NpmA using the M9
medium (10).
NpmA variants with alanine substitutions used for
analysis in functional assays were expressed and puriﬁed
following a simpliﬁed procedure. E. coli BL21(DE3)pLysS
cells harboring the expression vector pET-25b(+) with dif-
ferent npmA variants were grown in LB medium supple-
mented with ampicillin (100mg/l) and chloramphenicol
(34mg/l) at 37 C until the OD600 of 0.6–0.8. The expres-
sion was induced with 1mM IPTG and carried out at
37 C for 3 h with the addition of 3% ethanol. Cells
were pelleted by centrifugation (3500 g, 10min, 4 C),
frozen at  80 C and the pellet was resuspended in 40ml
of lysis buffer [50 mM NaH2PO4, pH 8.0, 300mM NaCl,
10mM imidazole and a cocktail of protease inhibitors
(Roche)]. Following sonication, the debris was removed
by centrifugation at 20 000 g for 20min at 4 C. Clariﬁed
supernatant was incubated for an hour at 4 C with the
Ni-NTA Agarose (Qiagen) equilibrated with the lysis
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sequently washed with the wash buffer (50mM NaH2PO4,
pH 8.0, 300mM NaCl, 20mM imidazole). The protein
was eluted with the elution buffer (50mM NaH2PO4,
pH 8.0, 250mM NaCl, 5% glycerol, 5mM BME,
200mM imidazole) and dialyzed against 20mM Tris–
HCl pH 7.5, 250mM NH4Cl, 10mM MgCl2,6 m M
BME, 10% glycerol. All NpmA variants were puriﬁed to
95% homogeneity judged by the SDS-polyacrylamide gel
electrophoresis.
Crystallization and data collection
Puriﬁed NpmA was complexed with the cofactor S-adeno-
sylmethionine (AdoMet) and reaction by-product S-adeno-
sylhomocysteine (AdoHcy) at 1:12 (NpmA:AdoMet/
AdoHcy) molar ratio. Crystallization trials were carried
out at room temperature by hanging-drop vapor-diffusion
method using crystallization screens from Hampton
Research (Aliso Viejo, CA, USA) and Jena Bioscience
screens (Jena, Germany). Initially crystals of NpmA and
NpmA–AdoMet/AdoHcy complexes were obtained from
the Jena Bioscience screens. Subsequently these conditions
were optimized to obtain the diffraction quality crystals.
The best crystals of NpmA alone or with AdoMet/
AdoHcy were obtained by mixing 1ml of concentrated
protein with 1ml crystallization solution [0.1 M citrate
pH 5.5, 20% (w/v) PEG 4000 and 10% (v/v) 2-propanol
for NpmA and NpmA-AdoMet complex; 30% (w/v) PEG
4000, 0.1 M sodium acetate, pH 4.6 and 0.2 M ammonium
sulfate for NpmA-AdoHcy complex] and were grown up
to 8 days.
Prior to data collection, crystals were brieﬂy soaked in
a cryoprotectant consisting of the paraton and mineral
oil in a 1:1 ratio, and ﬂash cooled in a N2 cold stream
(100 K). A complete single wavelength anomalous disper-
sion (SAD) data set was collected for the NpmA–AdoHcy
complex at the beamline X8C, NSLS, Brookhaven
National Laboratory using a Quantum4-CCD detector
(Area Detector Systems Corp Poway, CA, USA) to 1.9A ˚
resolution. The NpmA data set was collected using the
rotating anode generator (Bruker X8 Proteum) equipped
with PLATINUM135 CCD detector, whereas the high-
resolution NpmA–AdoHcy and NpmA–AdoMet complex
datasets were collected at beamline BL13B1, NSRRC
(Taiwan) using a ADSC Quantum-315 CCD Area
Detector. All the data sets were processed and scaled
using the program HKL2000 (11). The crystallographic
and reﬁnement statics are provided in Table 1.
Structure solution and reﬁnement
The expected eight selenium sites in one asymmetric unit
of the NpmA–AdoHcy complex crystal were located using
the program Solve (12). The overall ﬁgure of merit was
0.77. The resultant electron density map was of good
quality to automatically build over 80% of the model
using wARP (13). The remaining part of the model was
manually built using the program COOT (14). Alternating
cycles of model building and reﬁnement using the
programs CNS and REFMAC was carried out (15, 16)
with appropriate entries made in the dictionary for
AdoHcy. The ﬁnal R-factor is 0.21 (Rfree is 0.24) up to
1.9A ˚ resolution. The structure of apo-NpmA, NpmA–
AdoMet complex and the high-resolution NpmA–
AdoHcy complex (1.68A ˚ ) was solved by molecular
replacement method using MOLREP (17) with the
NpmA coordinates of the NpmA–AdoHcy complex as a
search model. The overall geometry of the ﬁnal models
was analyzed by PROCHECK (18).
Isothermal titration calorimetry (ITC)
NpmA in a buffer consisting of 20mM HEPES sodium,
pH 7.5, 250mM NaCl, 5% glycerol, 5mM BME and
10mM MgCl2 was titrated against S-adenosyl methionine
(AdoMet/AdoHcy, MP Biomedicals) solution prepared by
dissolving the AdoMet in the same buffer as the protein to
a ﬁnal concentration of 100mM. The ITC experiments
were carried out using VP-ITC calorimeter (Microcal,
LLC) at 20 C using 0.02–0.07mM protein in the sample
cell and 2–5mM AdoMet/AdoHcy in the injector. All
samples were thoroughly degassed and centrifuged.
Injection volumes of 8–10ml per injection were used for
different experiments and for each experiment the heat of
dilution for the ligand was measured. To restore the
baseline, successive injections were separated by at least
4min. The ITC data was analyzed by a single site-ﬁtting
model using Origin 7.0 (OriginLab Corp.) software.
Determination of the minimum inhibitory concentration
of kanamycin
Kanamycin minimum inhibitory concentration (MIC) was
determined in E. coli BL21(DE3)pLysS cells carrying
recombinant pET-25b(+) vector with different npmA
variants using the MIC dilution assay with small modiﬁ-
cations of a procedure described previously. In brief, over-
night cultures of BL21 (DE3) pLysS cells carrying mutant
genes in pET-25b (+) vector were diluted 100-fold in fresh
LB medium supplemented with ampicillin (100mg/l) and
chloramphenicol (34mg/l) and grown until the OD600 of 1.
Two hundred microliter of LB medium containing ampi-
cillin, chloramphenicol and various concentration of
kanamycin (0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256, 512 and
1024mg/l) was inoculated with 10
5 cells and grown in
microtiter plates in total volume for 18 h at 37 C. MIC
was determined as a minimal concentration of kanamycin
that prevents the visible growth of bacteria.
Isolation of 30S ribosomal subunits
Tetra-(His)6-tagged 70S ribosomes were isolated from
E. coli JE28 cells (obtained from Dr Suparna Sanyal
from Uppsala University, Sweden) using nickel-afﬁnity
chromatography, as a modiﬁcation of a method described
in ref. (19). Cells were harvested at OD600 of 1, cooled
slowly to 4 C, pelleted and resuspended in the lysis
buffer [20 mM Tris–HCl, pH 7.6, 10mM MgCl2,
150mM KCl, 30mM NH4Cl, 0.5 g/l lysozyme, 10mg/l
DNaseI, protein inhibitor cocktail (Roche)]. The suspen-
sion was lysed by sonication and cell debris was removed
by two centrifugation cycles at 20 000g for 10min. Lysate
was applied to a HiTrap
TM Chelating HP column (1ml,
GE Healthcare) equilibrated with the lysis buffer. Column
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baseline. Tetra-(His)6-tagged 70S ribosomes were eluted
with the elution buffer (20mM Tris–HCl, pH 7.6,
10mM MgCl2, 150mM KCl, 30mM NH4Cl, 150mM
imidazole) and dialyzed four times for 10min against the
low-Mg
2+ buffer (20mM Tris–HCl, pH 7.6, 1mM MgCl2,
150mM KCl, 30mM NH4Cl) to enable separation of
subunits and then applied to a HiTrap
TM Chelating
HP column (1ml, GE Healthcare) equilibrated with the
same buffer. As 30S subunits lack His-tag, they were
collected in the ﬂow through and concentrated by ultraﬁl-
tration (Amicon Ultra-15 Centrifugal Filter Unit with
Ultracel-30 membrane, cutoff 30kDa).
Methylation assay
The activity of NpmA and its variants was determined
using a modiﬁcation of a procedure described in Axis
Homocysteine Enzyme Immuno Assay kit (Axis-Shield
Diagnostics Ltd.). The concentration of AdoHcy
produced in the NpmA-catalyzed methyl transfer is
proportional to the concentration of methylated RNA
and production of AdoHcy (or indirectly m
1A1408) and
is monitored in a competitive ELISA assay using
anti-AdoHcy antibodies. Reactions for in vitro methyla-
tion contained 4pmol of 30S subunits, 100pmol of
AdoMet (Sigma) and 8pmol of NpmA. All reactions
were carried out for 45min at 37 Ci n5 0 mlo f2 0 m M
Tris–Cl, pH 6.5, 100mM NH4Cl, 10mM MgCl2,6 m M
BME with 10 % glycerol. Reactions were stopped by the
addition of 1ml of 0.5 M EDTA. Twenty-ﬁve microliter of
reaction mixtures were then transferred to the microtiter
plate wells coated with immobilized AdoHcy-BSA conju-
gate and incubated 30min with 200ml of mouse mono-
clonal anti-AdoHcy antibodies. Subsequently, wells
were washed four times with 350ml of the wash buffer
provided in the kit and incubated 20min with 100mlo f
rabbit anti-mouse antibodies conjugated with the horse-
radish peroxidase. Following the wash step, the detection
was initiated with the addition of 100ml of the perox-
idase substrate. Reaction was terminated after 20min
by the addition of 100ml of sulphuric acid and absorb-
ance was measured on 450nm using a microplate
reader. Concentration of AdoHcy was determined using
AdoHcy calibration curve that was prepared using control
AdoHcy samples provided in the kit. Duplicate samples
were measured in three independent experiments in
all cases.
Table 1. Crystallographic data and reﬁnement statistics
Data set AdoHcy AdoMet Apo-NpmA
b
SAD High resolution
b
Cell parameters (A ˚ ,  ) and
Space group
a=64.42,
b=64.42,
c=108.50, P43
a=64.98,
b=64.98,
c=108.42 P43
a=75.78,
b=64.42,
c=104.05,
 =100.08 P21
a=64.86,
b=64.86,
c=108.61, P43
Data collection
Resolution range (A ˚ ) 50–1.9 (1.93-1.90) 50–1.68 (1.71–1.68) 50–2.7 (2.75–2.70) 50–2.3 (2.34–2.3)
Wavelength (A ˚ ) 0.979 1.000 1.000 1.541
Observed reﬂections 422988 381987 75750 153501
Unique reﬂections 35024 51311 26821 19348
Redundancy 12.1 7.4 2.9 8.0
Completeness (%) 100 (100%) 100 (100%) 97.6 (95.2%) 96.5 (76.3%)
Overall (I/sI) 17.0 12.7 11.6 10.8
Rsym
a 0.08 (0.35) 0.07 (0.43) 0.13 (0.31) 0.102 (0.26)
Reﬁnement and quality
Resolution range (A ˚ ) 20–1.90 20–1.68 50–2.7 15–2.4
Rwork
c (no. of reﬂections) 0.21 (31257) 0.196 (41928) 0.252 (21257) 0.20 (14201)
Rfree
d (no. of reﬂections) 0.24 (1745) 0.232 (4701) 0.284 (2677) 0.26 (1576)
RMSD bond lengths (A ˚ ) 0.008 0.005 0.010 0.006
RMSD bond angles ( ) 1.09 1.226 1.398 1.15
Average B-factors
e (A ˚ 2)
Main chain (# atoms) 20.14 (852) 19.39 (860) 44.41 (844)
f 30.04 (852)
Side chain (# atoms) 22.19 (745) 26.46 (748) 46.40 (728)
f 36.64 (741)
Ligand (# atoms) 20.05 (27) 17.25 (27) 24.35 (28) –
Waters (# atoms) 32.52 (321) 35.25 (489) 34.225 (74) 40.37 (259)
Ramachandran plot
Most favored regions (%) 96.3 95.3 87.9 92.7
Additional allowed regions (%) 3.7 4.2 11.9 7.3
Generously allowed regions (%) 0.0 0.6 0.1 0.0
Disallowed regions (%) 0.0 0.0 0.0 0.0
aRsym=|Ii   <I>|/|Ii|, where Ii is the intensity of the i-th measurement, and <I> is the mean intensity for that reﬂection.
bFor all models, reﬂections with I>sI was used in the reﬁnement.
cRwork=||Fobs| |Fcalc||/|Fobs|, where Fcalc and Fobs are the calculated and observed structure factor amplitudes, respectively.
dRfree=as for Rwork, but for 10% (5% for NpmA–AdoHcy SAD data) of the total reﬂections chosen at random and omitted from reﬁnement.
eIndividual B-factor reﬁnements were calculated.
fFour molecules (chains A–D) in the asymmetric unit. D chains shows high B-factor values and it is not included in the averaging. However, it has
continuous well-deﬁned electron density map.
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Total rRNA was extracted from E. coli BL21(DE3)pLysS
cells carrying the expression vector pET-25b(+) with and
without the variants of the npmA gene using GenElute
Mammalian Total RNA Miniprep Kit (Sigma). Brieﬂy,
cells were harvested in early log phase (OD450 of
0.4–0.5), lysed by sonication and cell debris was
removed by two centrifugation cycles at 20000g for
10min. Total RNA was then prepared from the lysates
using the RNA cleanup protocol. A 50-Cy5-modiﬁed
deoxynucleotide primer, complementary to 16S rRNA
from nucleotides 1459 to 1479, was hybridized to the
rRNA and extended with AMV reverse transcriptase
(Finnzymes) (20). Sequencing reactions were performed
on rRNA isolated from E. coli cells lacking NpmA.
Extension products were separated on 6% denaturing
polyacrylamide gels and were visualized on Typhoon
9210 imager (GE Healthcare).
Chemical probing of 30S subunit–NpmA complex
Chemical probing was performed with DEPC and CMCT
as described in (21). Brieﬂy, 10pmol of 30S subunits were
incubated with a 2-fold molar excess of NpmA and 1mM
AdoHcy in either modiﬁcation buffer A (50mM HEPES-
KOH, pH 8.0, 10mM MgCl2, 100mM KCl, 5mM
dithiothreitol) or B (200mM HEPES-KOH, pH 7.8,
10mM MgCl2, 100mM KCl) for 30min at 37 Ci n5 0ml
reaction mixtures. Control reactions contained no
AdoHcy. The complexes were modiﬁed with either 50ml
of CMCT (42mg/ml in modiﬁcation buffer A) for 10min
at 37 C, or 1ml of DEPC for 30min at room temperature.
RNA was puriﬁed immediately with a GenElute
Mammalian Total RNA Miniprep Kit (Sigma), RNA
cleanup protocol. Chemical modiﬁcations were detected
by primer extension analysis using AMV reverse tran-
scriptase (Finnzymes) and 50-Cy5 modiﬁed deoxyoligonu-
cleotides complementary to the 16S rRNA sequences
1459–1479, 939–955 and 817–833. The cDNA products
of primer extension reactions were separated on 6% poly-
acrylamide sequencing gel and visualized on Typhoon
9210 imager (GE Healthcare).
Bioinformatics analyses
To identify orthologs of NpmA, we used its sequence as a
query to search the non-redundant protein database with
PSI-BLAST (22). Sequences with signiﬁcant similarity to
NpmA were retrieved and aligned using MUMMALS
(23). The alignment was reﬁned based on the results
of structure predictions obtained from the GeneSilico
MetaServer (24). Based on structural superpositions
onto NpmA, the sequences of TrmB, TrmK, TrmI and
Sgm proteins were added to the alignment for comparison.
A model of the wt NpmA protein (with SelMet reverted
to Leu) was constructed using SwissModel (25). GRAMM
1.03 (26) was used to generate 10000 alternative docking
models (poses) between the NpmA–AdoMet complex and
the crystal structure of the small ribosomal subunit
(Protein Data Bank code 2I2P). The search was restricted
to the area within 50A ˚ radius from the A1408 nucleotide
residue. The following parameters were used: energy
scores for repulsion and attraction were 30 and 0, respect-
ively, grid size 64A ˚ , grid step 2.8A ˚ . The NpmA structure
was rotated with 10  angle intervals. Subsequently, all
10000 poses were ﬁltered using the Filtrest3D server
(27), to rank them according to the proximity of the N1
atom of A1408 and the methyl group of AdoMet bound
to NpmA. Top 100 variants have been clustered
with MAXCLUSTER (http://www.sbg.bio.ic.ac.uk/
 maxcluster/index.html), and a member of the largest
cluster that exhibited best shape complementarity and
minimal number of clashes between NpmA and the 30S
subunit was chosen as the representative model.
RESULTS
Overall structure
The structure of NpmA–AdoHcy complex was solved by
the SAD experiment, while the structures of the
apo-NpmA and NpmA–AdoMet complex were solved
by molecular replacement using NpmA–AdoHcy coordin-
ates as a search model. The electron density for the ﬁrst
and the last residue, loop region (aa 144–157) and the
C-terminal His-tag are not well deﬁned and these
residues are not included in the model (Figure 1). The
models were reﬁned to low R-values with good stereo-
chemical parameters (Table 1). In apo-NpmA and
NpmA–AdoHcy structures the asymmetric unit consists
of two molecules, whereas in the NpmA–AdoMet
complex, the asymmetric unit has four complex molecules.
However, crystal contacts are not very extensive;
Figure 1. Structure of NpmA. Ribbon representation of NpmA-
cofactor complex. The N- and C-termini are labeled. The cofactor
AdoHcy is depicted in brown. This ﬁgure and the following ﬁgures
in this article have been prepared by PyMol (14).
Nucleic Acids Research,2011, Vol.39, No. 5 1907suggesting that they are not biologically relevant and the
gel ﬁltration experiment showed that NpmA exists as a
monomer in solution (Supplementary Figure S1).
NpmA adopts a Class I methyltransferase fold consist-
ing of a seven-stranded b sheet (b5"–b4"–b3"–b6"–b7"–
b9#–b8"). A search for structurally similar proteins within
the PDB database was performed with DALI (28). NpmA
shows the highest structural similarity to TrmB from
Bacillus subtilis, PDB code 2FCA (29), with rmsd of
3.1A ˚ for 179 Ca atoms (Z-score=16.5; 13% sequence
identity) and to a number of its bacterial and eukaryotic
orthologs from the TrmB/Trm8 family. TrmB is a guano-
sine-N
7 methyltransferase that speciﬁcally methylates the
G46 nucleotide in tRNAs. A common feature of NpmA
and TrmB that distinguishes them from all other Class I
MTases identiﬁed so far is that the N-terminal helix
(corresponding to motif X) folds onto the opposite part
of the central b-sheet (Figure 1) compared to other
enzymes of this fold (30). The space vacated by the
N-terminal helix is instead occupied by a TrmB/
NpmA-speciﬁc insertion between strands b8 and b9,
which in NpmA comprises two short helices, and in
TrmB one helix and a loop. Thus, NpmA and TrmB
should be considered closely homologous enzymes
sharing the same idiosyncrasies within the RFM super-
family. According to DALI searches, NpmA shares struc-
tural similarities with other RFM-fold proteins with
predicted or determined methyltransferase activity, but
they are all more distant than members of the TrmB
family (Supplementary Table S2).
NpmA–AdoMet/AdoHcy interactions
The ligands in NpmA–AdoMet and NpmA–AdoHcy
complexes display a similar mode of binding (Figure 2;
Supplementary Figure S3). The highly conserved consen-
sus motif G G G (G32 G G36) in the loop con-
necting the b3 to its successive a helix forms the bottom
of the cofactor-binding site, while residues D30, N38, P56,
Figure 2. Stereo view of the cofactor binding site in the active site region (A) NpmA–AdoMet complex: the Fo Fc simulated annealing (SA)-omit
map of the cofactor AdoMet contoured at 2s is shown. AdoMet is shown in cyan. (B) NpmA–AdoHcy complex: the Fo Fc SA-omit map of the
AdoHcy contoured at 3s is shown. AdoHcy is shown in brown. Ligands and all atoms within 3A ˚ were omitted prior to reﬁnement. (C) Stereo view
of the superposition of the ligand binding site of NpmA–AdoMet and NpmA–AdoHcy complexes. AdoHcy is shown in brown and AdoMet in cyan,
respectively. The residue G32 that makes hydrogen bonding contact with carboxypropyl moiety of AdoMet/AdoHcy is not shown for the clarity.
1908 Nucleic Acids Research, 2011,Vol.39, No. 5T109, E88, A87, D55, G32, L104 and S195 delineate the
cofactor-binding site (Figure 2). The residues D30, G32
and D55 are highly conserved in Class I AdoMet depend-
ent MTases and are involved in cofactor binding. D30
coordinates the carboxypropyl moiety via two water
molecules and D55 coordinates both hydroxyls of the
ribose moiety. The residues equivalent to E88, A87 and
L104 of NpmA have also been found to interact with the
cofactor in other MTases (31). In particular the side chain
of E88 (like its equivalents in other related enzymes)
coordinates the exocyclic amino group of the AdoMet
adenine moiety, while L104 and A87 are engaged in
hydrogen bonds with the cofactor via their backbone.
The adenine moiety is stacked between the side-chains of
P56 and L110, and its N7 atom is additionally coordinated
by the side chain of T109. Besides, residues N38, G32,
L104 and S195 interact with the carboxypropyl moiety
of AdoMet/AdoHcy. In total, NpmA makes 10 direct
hydrogen bonds with AdoMet/AdoHcy. The cofactor
binding site in apo-NpmA is highly similar to that of the
NpmA–AdoMet/AdoHcy complex, with the exception of
the D55, whose side chain exhibits a slightly different
orientation than in the cofactor-bound complexes.
In order to study the predicted cofactor-binding role of
residues D30, D55, E88, T109 and S195, we used site-
directed mutagenesis to generate alanine substitutions in
the respective positions. We analyzed the cofactor binding
ability and methylation activity of the corresponding
protein variants in vitro by a methylation assay
(Figure 3) and in vivo by comparing them with the wt
enzyme in their ability to render bacteria resistant to kana-
mycin (Table 2). We also identiﬁed the presence of
methylated A1408 in cells expressing different NpmA
variants by primer extension on 16S rRNA (Figure 4).
Interestingly, the only residue we found critical for the
NpmA activity is D30. The D30A variant was almost
completely unable to render bacteria resistant to kana-
mycin, its methylation activity in vitro was reduced to
nearly 20% activity of the native enzyme and primer
extension analysis revealed that m
1A1408 was present in
minimal amounts in 16S rRNA isolated from cells
expressing D30A. Surprisingly, D55 that coordinates the
ribose moiety of the cofactor via two hydrogen bonds was
found to be important, but not crucial for the NpmA
methyltransferase activity. The kanamycin MIC and
enzyme activity of D55A were reduced to 50%
compared to the wt NpmA, but the reverse transcriptase
stop due to the m
1A modiﬁcation on nucleotide A1408 in
the primer extension analysis was clearly visible.
Furthermore, E88A, T109A and S195A variants showed
no substantial difference from the wt enzyme in their
methyltransferase activity, as shown by all in vivo and
in vitro activity tests.
To gain more insight into AdoMet/AdoHcy binding
ability of unexpectedly active D55A, E88A, T109A,
S195A and D30A protein variants versus the wt enzyme,
we analyzed these proteins by ITC (Figure 5,
Supplementary Figure S5 and Table 3). The dissociation
constant (Kd) for AdoMet and AdoHcy of the wt NpmA
was determined to be 20mM with N=1.1 and 0.6mM with
N=1.0, respectively. The Kd for AdoMet (18mM) is com-
parable to that of the Sgm methyltransferase, whereas the
Kd for AdoHcy is 500 times higher than that of Sgm (21).
Figure 3. Relative activities of NpmA variants expressed with respect to the wild-type enzyme.
Table 2. Effects of NpmA single mutations on kanamycin resistance
NpmA variant Target Kanamycin
MIC (mg/l)
Negative control (empty vector) – 4–8
NpmA-wt – 1024
D30A AdoMet binding 8
D55A AdoMet binding 512
E88A AdoMet binding 1024
P106A A1408 binding/catalysis 1024
W107A A1408 binding/catalysis 8
T109A AdoMet binding 1024
F177A RNA binding 1024
S195A AdoMet binding 1024
W197A A1408 binding/catalysis 8
K199A RNA binding 1024
R200A RNA binding 1024
R205A RNA binding 1024
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weaker, with Kd values of 0.4mM and 2mM for AdoMet
and AdoHcy, respectively. Interestingly, the Kd of S195A
for AdoHcy was found to be 33mM, but we observed a
complete loss of AdoMet binding, while the NpmA
variants D30A, D55A and E88A completely lost their
ability to interact with both AdoMet and AdoHcy. It
is surprising that S195A, E88A and D55A variants, for
which we could not detect cofactor binding in vitro,
showed remarkable activity in vivo. However, the ITC
experiments were performed in the absence of the
substrate, the 30S subunit.
NpmA-target adenine interactions
Spatially adjacent and conserved residues P106 and W107
from motif IV, F177 from motif VII and W197 from motif
VIII were predicted to form the adenosine binding pocket.
Notably W107 side chain adopts different conformation in
NpmA–AdoMet and NpmA–AdoHcy complexes. In
AdoMet complex, the indole ring of W107 moves closer
to the methyl group of the cofactor to enhance the inter-
actions, whereas the lack of methyl group in AdoHcy
keeps the side chain of W107 away from AdoHcy
(Supplementary Figure S2). The results of our functional
tests conﬁrmed the importance of the two Trp residues, as
the in vitro methylation activity of W107A and W197A
variants was signiﬁcantly reduced (to  15% of the wt
enzyme activity). Interestingly, m
1A1408 could not be
detected in 16S rRNA from the cells expressing the
altered proteins and they failed to cause any kanamycin
resistance in bacterial cells under the conditions tested.
P106A and F177A on the other hand, were as active
in vivo as the wt enzyme according to the amount of the
methylated 16S rRNA (Figure 4) and kanamycin resist-
ance (Table 2). We observed a decrease of activity in the
in vitro methylation assay, where P106A and F177A
showed  70 and 60% activity, respectively, compared
to the wt NpmA. This effect might be a consequence of
the protein instability outside the living cell, especially in
the case of F177A, where we observed a lower yield of the
puriﬁed protein (data not shown). W107 and W197 are
positioned similarly to aromatic residues in the active
sites of many other nucleic acid MTases that are known
to stabilize the target base via stacking interactions e.g.
DNA:m
6A MTase M.TaqI (32) or 23S rRNA:m
6,6A2058
MTase ErmC0 (33). Our structural and functional analyses
suggest that these two Trp residues function in a similar
manner in NpmA, by stabilizing the target adenosine in a
favorable position for the catalytic step. On the other
hand, the side-chains of P106 and F177 seem to have a
secondary and non-essential role in this process.
Guiding of the target base into the catalytic center of
MTases that modify nucleic acids is often accompanied by
interactions of positively charged residues exposed on the
enzyme surface with either DNA/RNA backbone or with
the nucleotide residues located next to the target (34–36).
We therefore analyzed three conserved residues K199,
K200 and R205 that are in the vicinity of the adenosine
binding pocket. Surprisingly, all three residues turned out
to be completely dispensable and no difference could be
found between the variants with individual alanine substi-
tutions and the wt NpmA. Our results differ from those
obtained for KamB enzyme, where the corresponding
R195 was found to be very important and R196 and
R201wereindispensablefortheMTaseactivityinvivo(37).
RNA footprinting of NpmA interaction with the 30S
ribosomal subunit
To obtain information about interactions between NpmA
and the 30S subunit, which was found to be the only
Figure 4. Gel image of a primer extension on rRNA isolated from cells expressing either wild-type or mutant forms of the NpmA enzyme. rRNA
was puriﬁed from the cells actively expressing an NpmA variant and extended with a primer complementary to the 1459–1479 region in 16S rRNA.
Dideoxy sequencing lanes (CUAG) were used to locate the site of modiﬁcation. Control rRNA was puriﬁed from cells expressing no NpmA. The
NpmA variant is indicated above the corresponding lane on the gel. The position of the reverse transcriptase stop due to the m
1A modiﬁcation on
nucleotide A1408 is noted on the right side of the gel image.
1910 Nucleic Acids Research, 2011,Vol.39, No. 5Figure 5. ITC experiments. (A) NpmA–AdoMet titration. (B) NpmA–AdoHcy titration. (C) D30A–AdoMet titration. (D) D30A–AdoHcy titration.
The upper panels show the injection proﬁle after baseline correction and the bottom panels show the integration (heat release) for each injection
(except the ﬁrst one). The ITC proﬁle for other variants such as D55A, E88A that are similar to D30A (no binding) are provided in the
Supplementary section. Similarly the remaining variants mentioned in the main text (e.g. T109A and S195A) are given in the Supplementary
section (Supplementary Figure S5).
Nucleic Acids Research,2011, Vol.39, No. 5 1911substrate methylatable in vitro (7), we performed DEPC
(speciﬁc for A) and CMCT (speciﬁc for G and U) probing
of 16S rRNA. The summary of the results is shown in
Figures 6 and 7. Chemical modiﬁcations in 16S rRNA
isolated from the MTase-treated 30S subunits were
detected by primer extension. We used primers comple-
mentary to the 16S RNA nucleotides 1459–1479,
939–955 and 817–833. This enabled us to examine the
regions that are proximal to the target A1408 in the
fully assembled 30S subunit and thus could form the puta-
tive binding site for NpmA. Chemical probing allowed us
to monitor the changes in the reactivity of nucleotides
upon NpmA binding, where nucleotides became either
less reactive (potentially protected from the water-
soluble reagent) or more reactive (potentially more
exposed to the water-soluble reagent). In addition, we
also observed a different pattern of reverse transcriptase
stops upon NpmA binding at nucleotides other than those
expected to react with either DEPC or CMCT. This effect
is often observed within regions with A and C residues and
may be caused e.g. by structural changes in the RNA after
its isolation from the 30S particles that were incubated
with NpmA, resulting from chemical modiﬁcations.
A distinct section containing the majority of nucleotides
that become protected upon NpmA binding was found in
helix 24 (between nucleotides 810 and 760). In addition, a
few protected nucleotides were also found in helices 22
and 23 (nucleotides 754, 706, 682, 665) and in helix 25
(nucleotide 880). In helices 26 and 26a, we observed a
few nucleotides that become exposed upon NpmA
binding. Binding of NpmA results in protection of nucleo-
tides in helices 42 and 43 (residues 1299–1362) and
exposure of residues in helix 41. It is remarkable that
the target nucleotide residue A1408 was not found to be
protected by NpmA. Instead, two distinct regions
upstream of A1408 (including nucleotides 1388–1390,
1392, 1393, 1395, 1397 in helix 28 and 1404, 1406
and 1407 in the top part of helix 44) showed enhanced
reactivity as a result of NpmA-induced structural changes.
Model of the NpmA-30S subunit complex
To predict the three-dimensional mode of protein–
substrate interactions, we docked the NpmA–AdoMet
complex to the 30S subunit structure, with a restraint
imposed as to minimize the distance between the methyl
group of AdoMet and the target nucleoside A1408
Figure 6. Fluorescent image of a primer extension gel showing chemical footprinting of NpmA methyltransferase on the 30S ribosomal subunit. The
30S subunit was incubated at 37 C with 2-fold molar excess of NpmA with or without the presence of SAH. Samples were modiﬁed with CMCT and
DEPC. 16S rRNA was puriﬁed from the subunits and analysed by primer extension from primer 817–833 (A), 939–955 (B)and 1459–1479 (C). Each
lane on the gel images is marked as follows: dideoxy sequencing lanes (CUAG) were used to locate the sites of modiﬁcations; control rRNA was
puriﬁed from the chemically untreated 30S subunits; CMCT- and DEPC- show primer extension on rRNA isolated from 30S subunits treated with
the chemical, but not incubated with SAH and NpmA; CMCT+ and DEPC+ show primer extension on rRNA isolated from 30S subunits treated
with the chemical and incubated with SAH and NpmA. Nucleotides that were protected upon NpmA binding are marked with a black triangle
(CMCT) or a black dot (DEPC). Nucleotides that were exposed upon NpmA binding are marked with a grey triangle (CMCT) or a grey dot
(DEPC). Helix numbering is indicated in boxes. Intervening lanes were removed for the clarity of the presentation.
1912 Nucleic Acids Research, 2011,Vol.39, No. 5Figure 7. Panel I. Schematic representation of chemical footprinting of NpmA methyltransferase on the 30S ribosomal subunit. Samples were
modiﬁed with CMCT and DEPC. RNA was puriﬁed from 30S subunits and analysed by primer extension from primer 817–833 (A), 939–955
(B)and 1459–1479 (C). Nucleotides found protected upon NpmA binding are marked with a black triangle (CMCT) or a black dot (DEPC).
Nucleotides found exposed upon NpmA binding are marked with a grey triangle (CMCT) or a grey dot (DEPC). Regions showing enhanced
non-speciﬁc reactivity with chemicals (indicating local structural changes caused by NpmA binding) are circled. Helix numbering is indicated in
boxes. Panel II. Mapping of footprinting data onto the 30S structure and the model of NpmA-30S complex. Components of the 30S subunit are
shown in the surface representation. NpmA is shown as a solid ribbon in blue. Ribosomal proteins and regions of 16S rRNA not analyzed by
footprinting are indicated in light grey. Results of the footprinting experiments are color coded as follows: residues with unchanged reactivity are
shown in white, residues relatively more reactive in the footprinting experiment are shown in red, residues less reactive in the footprinting experiment
are shown in green. The target A1408 is shown in orange.
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representative model obtained after clustering of
best-ﬁtting poses (Figure 7), NpmA and the 30S subunit
ﬁt together relatively tightly, suggesting that no large-scale
conformational changes are required for the binding to
occur. NpmA is predicted to interact directly only with
16S rRNA, and not with ribosomal proteins. In our
docking model most of the contacts with the RNA are
mediated by the positively charged N-terminal region
(with the 30 major 16S rRNA domain) and by the catalytic
face of NpmA (with the central and 30 minor 16S rRNA
domains). No direct contacts are formed with the 50
domain. The region comprising residues 144–157 of
NpmA, for which coordinates could not be built in the
crystal structure, is located close to the target base, but its
anchor points remain exposed on the protein surface in the
complex. We predict that this region is unstructured in the
unbound form of NpmA, but may become structured
upon formation of the NpmA-30S subunit complex.
While the methylatable N1 atom of A1408 does not
make a direct contact with the enzyme, the target base
can be positioned within the active site of NpmA
(between W107 and W197 residues) after being simply
rotated out of the helix. It is worthwhile to mention that
in the 30S subunit structure, A1408 is stacked within helix
44, but not base-paired, hence its ﬂipping may be relatively
easy. In summary, the docking model supports the inter-
pretation of the experimental data that only limited con-
formational changes in the 30S subunit, including A1408
base ﬂipping, are required for NpmA to methylate its
target in 16S rRNA.
DISCUSSION
The nucleotide residue A1408 in 16S rRNA of the 30S
ribosomal subunit is a crucial ‘hot spot’ of aminoglycoside
resistance. The universally conserved A1408 has a critical
role in binding of aminoglycoside antibiotics to the A
site of 16S rRNA. Structural studies have shown that
the hydroxyl group on sugar ring I of 4,6- and
4,5-disubstituted 2-deoxystreptamines forms hydrogen
bonds with the N1 and N6 atoms of A1408 (38–40). The
N1 methylation of A1408 by NpmA apparently disrupts
the interaction of the 16S rRNA with the drug, as
indicated in footprinting experiments (7) thereby
conferring resistance. The recent detection of the Kam
family member NpmA in a clinical isolate (7) indicates
an imminent threat to the utility of aminoglycosides
as antibacterial drugs and warrants attention. The struc-
ture of NpmA and its complex with the cofactors and
substrate holds key to understanding its mode of action
and potentially to develop speciﬁc inhibitors of the A1408
methylation activity that could reinstate the activity of
aminoglycoside antibiotics.
Based on structural analyses we identiﬁed residues in
NpmA potentially important for cofactor-binding and ca-
talysis and carried out site-directed mutagenesis to obtain
protein variants with alanine substitutions in the corres-
ponding positions. As predicted, the ITC experiments
revealed that NpmA variants with cofactor-binding
residues substituted by Ala have completely lost or
exhibited signiﬁcantly reduced ability to bind AdoMet
or AdoHcy (Figure 5, Supplementary Figure S5 and
Table 3). We were, however, greatly surprised by the
fact that the variant D55A retained the ability to carry
out m
1A1408 methylation in vitro, as well as to render
the host-cell resistant to aminoglycosides, because substi-
tutions of this conserved residue in other RNA
methyltransferases, e.g. D55 in KamB (37) or D156 in
Sgm (41) has lead to drastic reduction of these enzymes’
activity both in vivo and in vitro. We speculate that while
the D55A variant of NpmA cannot form a binary complex
with the cofactor, it may bind AdoMet and methylate the
target when it is already engaged in interactions with the
substrate. For some related methyltransferases, e.g. Dam
enzyme from phage T4 phage, it has been demonstrated
that the binding of the methyl group donor or the nucleic
acid substrate reciprocally improve the afﬁnity for each
other in the ternary complex (42). This suggests that
NpmA may also exhibit signiﬁcantly increased afﬁnity
for AdoMet when pre-bound to the 30S subunit. Other
enzymes, however, e.g. Dam from E. coli (which is very
closely related to T4 Dam), exhibit similar afﬁnity
for AdoMet in the presence or in the absence of the
substrate (43). Apparently, large variations of parameters
concerning the binding of the ligands and their mutual
interactions are not uncommon among related
methyltransferases. We speculate that in NpmA, binding
of the 30S substrate increases the afﬁnity for AdoMet to
such extent that it can rescue the ligand binding ability of
the D55A variant, while the similar effect has not been
observed for KamB. Our results show that the relative
importance of ‘the same’ residues in closely related
proteins may vary. This study highlights the importance
of comparative biochemical and functional analyses of
proteins that belong to the same family and suggests
that structural and functional characterization of just
single members of each protein family (as in the structural
genomics approach) may be insufﬁcient to understand
sequence-structure–function relationships in proteins.
The ﬁnding that the side chain of D55 residue is dispens-
able for the in vivo activity of NpmA, and hence that mu-
tations altering that residue may appear in the nature, has
to be taken into consideration in analyses aiming at
structure-based design of inhibitors.
NpmA binding to the 30S subunit
NpmA was found to successfully methylate only fully
assembled 30S subunits, while the entire 70S ribosome
Table 3. ITC results
NpmA variant Kd for AdoMet Kd for AdoHcy
Wild-type 20mM 0.6mM
D30A No binding No binding
D55A No binding No binding
T109A 0.4mM 2mM
S195A No binding 33mM
E88A No binding No binding
1914 Nucleic Acids Research, 2011,Vol.39, No. 5or naked 16S rRNA could not be methylated (7). This
reactivity towards 30S subunits is analogous to
aminoglycoside resistance MTases from the Arm family,
ArmA and Sgm, which methylate G1405 (44,45). Here we
present the analysis of interactions between a member of
the Kam family and small ribosomal subunit as its sub-
strate. Using DEPC and CMCT chemical probing and
subsequent primer extension analysis we were able to
identify helices 24 and 42 with associated loop as
primary regions that interact with NpmA. In addition,
two short sections of 16S rRNA 50 from the target
nucleotide residue A1408 showed increased non-speciﬁc
reactivity to chemicals when isolated from 30S subunits
incubated with the NpmA. This might be the result of a
local structural change in the rRNA caused by NpmA
binding, suggesting that NpmA-30S interaction could be
associated with the top of helices 44 and 28 as well.
We have recently reported a similar footprinting and
docking analysis for Sgm MTase from the Arm family
that modiﬁes G1405 (21). While G1405 and A1408 are
positioned very closely in rRNA, suggesting a similar
mode of binding for Sgm and NpmA, we could not
clearly deﬁne the region(s) of 16S rRNA that form dis-
tinctive interactions with Sgm. Instead, protected nucleo-
tides were scattered over a wide area, together with a large
number of nucleotides with the activity enhanced upon
Sgm binding, indicating complex structural changes of a
rather global character that enable the otherwise buried
G1405 base to become available for methylation by Sgm.
Unlike Sgm, NpmA binding to the 30S subunit does not
lead to global structural rearrangements; instead we
observe only local changes. Remarkably, the target base
A1408 was not found to be protected upon NpmA
binding, which suggests that it may be ﬂipped-out and
more solvent accessible in the complex with the enzyme
than in the 30S subunit before modiﬁcation. Its binding
may be stabilized in the NpmA active site by residues
W107 and W197, found here to be essential for the methy-
lation to occur in vivo. The conformation of W107 side
chain is different in complexes with AdoMet and AdoHcy,
which suggests that limited conformational changes upon
binding may occur also on the protein side. In the crystal
structures of NpmA, the side-chains of these Trp residues
are too close to each other to enable binding of the target
base, but a simple change to alternative rotamers allows
the protein to form a binding pocket to accommodate the
adenine moiety (data not shown). The necessity of minor
conformational adjustments has to be taken into consid-
eration in the future analyses aiming at structure-based
design of inhibitors.
The results of footprinting experiments with Sgm and
NpmA are in perfect agreement with the docking studies.
In our previous work (21) we found that the Sgm structure
cannot be docked to its target G1405 without very severe
steric clashes with the 30S subunit, which implies that sig-
niﬁcant conformational changes upon its binding must
occur. On the other hand, NpmA can be easily docked
to its target A1408, to form a relatively close-ﬁtting
complex with the 30S subunit. Therefore we postulate
that Sgm and NpmA use very different mechanisms to
access their target bases.
Regions of 16S rRNA that we found to be involved in
interactions with NpmA come in close proximity and form
functional sites in fully assembled 30S subunits, including
the decoding site and site of association with 50S subunit,
which clearly explains why NpmA cannot act on 70S ribo-
somes. In addition, regions identiﬁed as NpmA binding
sites partly overlap with the KsgA-30S interaction sites
identiﬁed by directed and solution hydroxyl radical foot-
printing that include helices 2, 11, 24, 27, 28, 44 and 45
and loop 790 (46). KsgA is a housekeeping
dimethyltransferase that modiﬁes A1518 and A1519
(both to m
6,6A) in helix 45 of 16S rRNA. It acts as a
regulator of ribosome biogenesis and binds to immature
30S subunits in a translationally inactive conformation
(47). NpmA is known to act on mature 30S subunits,
but it has not been determined whether it can methylate
any of the reconstitution intermediates (RIs) in the 30S
subunit assembly. The ﬁrst intermediate, RI, lacks
tertiary ribosomal proteins S2, S3, S10, S14 and S21 in
central and 30-domain and is not competent to form a
small ribosomal subunit. rRNA in RI undergoes an exten-
sive conformational rearrangement to form RI*, which
can then bind the remaining ﬁve ribosomal proteins and
form 30S subunit (48). Holmes and Culver have per-
formed an extensive analysis of conformational changes
in 16S rRNA during the assembly of small ribosomal
subunit (49) and mapped structural differences between
the assembly intermediates RI and RI* (50). The
majority of conformational changes related to the
central and 30-domain of the 30S subunit occur during
transition from RI to RI*. These changes include func-
tional sites on 30S, where NpmA binds and recognizes
its target, hence we may propose that the earliest stage
that supports the NpmA action could be a nearly
assembled RI* of the 30S subunit.
Relationship of NpmA to other MTases; insight from
structural analyses
The availability of a high-resolution NpmA structure
allowed us to establish its relationship to other MTase
families. NpmA is a member of the RFM superfamily
and exhibits a class I MTase fold with the exceptional
topological rearrangement involving the N-terminal
helix. The arrangement of the N-terminal helix in NpmA
is similar to those found in the structure of tRNA:m
7G56
MTase TrmB, a representative of a protein family that
appears to be the closest homolog of Kam-family
MTases (Supplementary Figure S6). It is very intriguing
that an RNA:m
1A MTase (NpmA) appears to be more
closely related to an RNA:m
7G MTase (TrmB) than to
other m
1A MTases, for which structures have been
determined, including tRNA:m
1A58 MTase TrmI (51)
and tRNA:m
1A22 MTase TrmK (52,53). NpmA is also
structurally distinct from Arm/RmtB/Sgm enzymes
that form m
7G1405 in 16S rRNA (Supplementary
Figure S6). G1405 is very close to A1408, the site of
methylation of NpmA. While NpmA/Kam and Arm/
RmtB/Sgm methyltransferases belong to the same RFM
superfamily and methylate bases that are very close to
each other in the 30S subunit leading to a similar
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biotics, their catalytic domains are not very closely
related and presumed substrate-binding domains are com-
pletely different.
Based on structural superposition we generated a
multiple sequence alignment involving all members of
the Kam family (including NpmA studied in this work),
as well as individual representatives of m
1A MTase
families TrmI and TrmK, and m
7G MTases TrmB and
Sgm (Supplementary Figure S4). Motifs I and II
involved in the binding of the common cofactor
AdoMet exhibit residues that are universally conserved
between these enzymes (in particular carboxylates
involved in coordination of the methionine and ribose
moieties). On the other hand, motifs IV, VI, and VIII
that commonly harbor residues involved in binding of
the target base and catalysis are completely different. In
the active sites, traces of similarity are observed only
between NpmA and TrmB enzymes: Y193 is homologous
and most likely functionally equivalent to the
base-binding residue W197 of NpmA. Both proteins also
share a common Phe residue (F116 in TrmB and F105 in
NpmA), which stacks face to edge with the above-
mentioned base-binding aromatic residue and thereby sta-
bilizes it. Other than that, however, the active sites of
TrmB and NpmA are different, consistent with the
activity on a different substrate: the N7 atom of guanosine
versus the N1 atom of adenosine.
The absence of common residues in motifs responsible
for catalysis suggest that m
1A MTases acting on different
RNA targets have non-homologous active sites and most
likely developed independently from different ancestors
within the RFM superfamily. In particular, our analysis
suggests that the Kam family evolved from the TrmB/
Trm8 family of m
7G MTases. This is in agreement with
the results of our phylogenetic analysis of the entire RFM
superfamily, in which the Kam, TrmI and TrmK families
of m
1A MTases do not form a single branch on the tree
and most likely have evolved independently (J.M.B. un-
published data). This situation resembles the polyphyletic
evolution of m
7G MTases, whose ﬁve families (Arm/Sgm,
TrmB/Trm8, RsmG, Abd1/Ecm1 and Bud23) are pre-
dicted to be independent evolutionary inventions with
the same fold but different active sites (21). Likewise, 20-
O-ribose MTases include several families of enzymes with
different speciﬁcities (e.g. RrmJ-like, HEN1 and Trm13)
that exhibit different active sites anchored to the common
RFM fold (54) or even to a different fold (55). Recently, a
family of RNA MTases of the SPOUT fold have been
characterized, in which some members exhibit m
1G speci-
ﬁcity (56), while others form m
1A but not m
1G or exhibit
dual speciﬁcity and generate m
1Ao rm
1G (57). This
variety of protein families and protein folds with different
active sites able to carry out RNA:m
1A methylation
suggests that this type of reaction is probably relatively
easy for an enzyme to evolve (e.g. from an MTase of a
different speciﬁcity). On the other hand, the uniqueness of
the adenosine-binding site of MTases from the Kam
family suggests that they may be good targets for the de-
velopment of Kam-speciﬁc inhibitors. The structural
analyses presented in this work provide a stepping stone
for structure-based virtual screening to ﬁnd candidates for
such compounds.
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